Latest Insider Transactions at Seres Therapeutics, Inc. (MCRB)
This section provides a real-time view of insider transactions for Seres Therapeutics, Inc. (MCRB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Seres Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Seres Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 30
2023
|
Teresa L. Young |
SELL
Open market or private sale
|
Direct |
2,907
-25.59%
|
$2,907
$1.35 P/Share
|
|
Oct 30
2023
|
Eric D. Shaff CEO and President |
SELL
Open market or private sale
|
Direct |
8,552
-6.89%
|
$8,552
$1.35 P/Share
|
|
Oct 30
2023
|
Paula Cloghessy Officer |
SELL
Open market or private sale
|
Direct |
2,904
-5.98%
|
$2,904
$1.35 P/Share
|
|
Oct 30
2023
|
Matthew R. Henn |
SELL
Open market or private sale
|
Direct |
3,886
-6.45%
|
$3,886
$1.35 P/Share
|
|
Oct 30
2023
|
Lisa Von Moltke |
SELL
Open market or private sale
|
Direct |
4,232
-30.79%
|
$4,232
$1.35 P/Share
|
|
Oct 30
2023
|
David S. Ege |
SELL
Open market or private sale
|
Direct |
4,066
-5.72%
|
$4,066
$1.35 P/Share
|
|
Oct 30
2023
|
Thomas Des Rosier Chief Legal Officer and EVP |
SELL
Open market or private sale
|
Direct |
4,156
-3.52%
|
$4,156
$1.35 P/Share
|
|
Oct 30
2023
|
David Arkowitz Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,066
-2.26%
|
$4,066
$1.35 P/Share
|
|
Oct 27
2023
|
Teresa L. Young |
BUY
Exercise of conversion of derivative security
|
Direct |
11,361
+50.0%
|
-
|
|
Oct 27
2023
|
Eric D. Shaff CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
27,838
+18.31%
|
-
|
|
Oct 27
2023
|
Paula Cloghessy Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,418
+16.24%
|
-
|
|
Oct 27
2023
|
Matthew R. Henn |
BUY
Exercise of conversion of derivative security
|
Direct |
12,623
+17.32%
|
-
|
|
Oct 27
2023
|
Lisa Von Moltke |
BUY
Exercise of conversion of derivative security
|
Direct |
13,745
+50.0%
|
-
|
|
Oct 27
2023
|
David S. Ege |
BUY
Exercise of conversion of derivative security
|
Direct |
11,361
+13.78%
|
-
|
|
Oct 27
2023
|
Thomas Des Rosier Chief Legal Officer and EVP |
BUY
Exercise of conversion of derivative security
|
Direct |
13,501
+10.26%
|
-
|
|
Oct 27
2023
|
David Arkowitz Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,209
+6.84%
|
-
|
|
Apr 28
2023
|
David S. Ege |
SELL
Open market or private sale
|
Direct |
7,038
-10.55%
|
$35,190
$5.19 P/Share
|
|
Apr 27
2023
|
David S. Ege |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+23.06%
|
-
|
|
Apr 27
2023
|
David Arkowitz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,500
+20.32%
|
-
|
|
Oct 31
2022
|
David S. Ege |
SELL
Open market or private sale
|
Direct |
5,012
-9.69%
|
$35,084
$7.93 P/Share
|
|
Oct 27
2022
|
David S. Ege |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+27.88%
|
-
|
|
Oct 27
2022
|
David Arkowitz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,500
+27.33%
|
-
|
|
Jul 05
2022
|
Nutritional Health Ltp Fund General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
8,738,243
+41.57%
|
$26,214,729
$3.15 P/Share
|
|
Jul 05
2022
|
Eric D. Shaff CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
63,492
+39.73%
|
$190,476
$3.15 P/Share
|
|
Jul 05
2022
|
Meryl Zausner Director |
BUY
Grant, award, or other acquisition
|
Direct |
31,746
+50.0%
|
$95,238
$3.15 P/Share
|
|
Jul 05
2022
|
Matthew R. Henn |
BUY
Grant, award, or other acquisition
|
Direct |
47,619
+50.0%
|
$142,857
$3.15 P/Share
|
|
Jul 05
2022
|
David S. Ege |
BUY
Grant, award, or other acquisition
|
Direct |
31,746
+50.0%
|
$95,238
$3.15 P/Share
|
|
Jul 05
2022
|
Thomas Des Rosier Chief Legal Officer and EVP |
BUY
Grant, award, or other acquisition
|
Direct |
63,492
+37.78%
|
$190,476
$3.15 P/Share
|
|
Jul 05
2022
|
Willard H Dere |
BUY
Grant, award, or other acquisition
|
Direct |
31,746
+50.0%
|
$95,238
$3.15 P/Share
|
|
Jul 05
2022
|
Paula Cloghessy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,746
+50.0%
|
$95,238
$3.15 P/Share
|
|
Jul 05
2022
|
David Arkowitz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,492
+49.22%
|
$190,476
$3.15 P/Share
|
|
Jul 05
2022
|
Richard N Kender |
BUY
Grant, award, or other acquisition
|
Direct |
63,492
+50.0%
|
$190,476
$3.15 P/Share
|
|
Jul 05
2022
|
Paul Biondi |
BUY
Grant, award, or other acquisition
|
Direct |
47,619
+50.0%
|
$142,857
$3.15 P/Share
|
|
Jun 15
2022
|
David Arkowitz Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+6.62%
|
-
|
|
May 17
2021
|
Nutritional Health Ltp Fund General Partner LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
295,171
-9.06%
|
-
|
|
Dec 01
2020
|
Matthew R. Henn |
SELL
Open market or private sale
|
Direct |
91,812
-77.81%
|
$2,478,924
$27.49 P/Share
|
|
Dec 01
2020
|
Matthew R. Henn |
BUY
Exercise of conversion of derivative security
|
Direct |
79,812
+30.91%
|
$399,060
$5.54 P/Share
|
|
Nov 23
2020
|
Stephen Berenson |
BUY
Other acquisition or disposition
|
Direct |
3,589
+50.0%
|
-
|
|
Nov 23
2020
|
Flagship Ventures Fund Iv General Partner LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
7,907,179
-56.35%
|
-
|
|
Jun 18
2019
|
Afeyan Noubar Director |
BUY
Open market or private purchase
|
Indirect |
8,888,888
+50.0%
|
$17,777,776
$2.25 P/Share
|